Phenothiazine Compounds Inhibit TNF-Alpha to Treat Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's Disease and other age-related conditions, including COVID-19, have been largely ineffective as they target the presumptive distal cause of the diseases, whereas the novel phenothiazine compounds described herein are discovered based on age-dependent phenotypes and assessed for their ability to reduce toxicity and inhibit microglial secretion of TNF-alpha, which drives the pathophysiology of these diseases.
Innovation Solution
The development of phenothiazine compounds, including specific structures such as TC84-31, TC84-37, TC84-32, and TC84-110, which are designed to reduce Abeta toxicity and microglial inflammation by inhibiting TNF-alpha secretion, as reflected in their efficacy in Abeta transgenic C. elegans models and mouse models of Alzheimer's Disease, and demonstrated to preserve motor and cognitive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs target Abeta itself, then Abeta aggregation is reduced in mouse models, but treatment fails in human AD trials
Solution Approach 1:
Instead of targeting Abeta aggregation directly (the conventional approach that failed), the patent inverts the strategy by targeting the downstream consequence - Abeta toxicity and microglial inflammation. The phenothiazine compounds block TNF-alpha secretion from microglia in response to Abeta, thereby treating the toxic effects rather than the aggregate itself, which translates across species more effectively
Solution Approach 2:
The patent introduces an intermediary mechanism - the phenothiazine compounds act as mediators that interfere with the signaling pathway between Abeta and microglial TNF-alpha secretion. By blocking this intermediary inflammatory response rather than the primary Abeta aggregate, the treatment achieves broader applicability across mouse and human models
2Reliability
If current approved drugs are used, then some cognitive benefits are achieved, but the benefits are modest and clinical significance is questioned
Solution Approach 1:
The patent changes the therapeutic parameter from targeting Abeta aggregation to targeting microglial inflammation and TNF-alpha secretion. This parameter shift addresses the underlying inflammatory drive of AD pathology rather than just the visible plaques, producing more clinically significant effects by modifying the disease process at a more effective level
3Adaptability or versatility
If multi-functional drugs or combinations are used, then treatment coverage is improved, but drug complexity increases
Solution Approach 1:
The phenothiazine compounds exhibit multi-functionality by simultaneously addressing multiple pathological features: they reduce Abeta toxicity, inhibit microglial activation, and block TNF-alpha secretion. This single compound performs multiple therapeutic functions that would otherwise require combination therapies, simplifying the treatment regimen while maintaining broad efficacy
Data Source
AI summary
Disclosed are phenothiazine compounds which reduce Abeta toxicity in vivo, reduce microglial inflammation as indicated by secretion of TNF-alpha, reduce intracerebral hemorrhage in vivo toxicity as indicated by preserved motor and cognitive function, and SARS-CoV-2 replication. Also disclosed are methods of use thereof for the treatment of disease in a subject in need thereof.